Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Should You Let AstraZeneca Go?

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

One of my biggest challenges as an investor is getting too attached to my investments. I've long been a fan of AstraZeneca (NYSE: AZN  ) , its drug pipeline, and the healthy dividend attached to that pipeline, which currently sits at a trailing yield of 4.6%. But I've been ignoring an important problem that could bring my relationship with this drugmaker to an abrupt end.

Is it time to let go?
Back in 2007, analysts predicted the demise of AstraZeneca. Five of its blockbusters would lose their patent protection over the following five years. Yet the stock has largely bucked that trend.

But after years of telling myself that this event was still in the future, I have to admit that it's finally here.

AstraZeneca lost patent exclusivity to its breast-cancer drug Arimidex in the U.S. in late June. It also faces upcoming patent expirations on its antipsychotic drug Seroquel and its asthma blockbuster Symbicort in the next couple of years.

Together, these three drugs made up a whopping 30% of AstraZeneca's revenue in the second quarter.

Generic vultures
Teva Pharmaceutical
(Nasdaq: TEVA  ) has not been shy about its plans to grab market share away from AstraZeneca with a generic form of Arimidex, called Anastrozole.

U.S. sales of Arimidex are likely to nosedive for AstraZeneca because of generic competition. Even in the second quarter, before the generic form came out, Arimidex sales in the U.S. dropped 17%.

You're giving me heartburn
AstraZeneca did score a victory in June, when it succeeded in keeping its largest drug by revenue, Crestor, under patent through 2016. But Nexium, which earned the company more than $1.25 billion last quarter, has patents that expire as early as 2014.

Putting these expirations aside, AstraZeneca's overall business has been less than stellar. Revenue growth has slowed to a crawl, and its attempts at pipeline growth via acquisition have struggled.

For example, AstraZeneca purchased MedImmune in 2007 for its infectious-diseases drug portfolio, including MedImmune's main revenue generator, Synagis, and the promising FluMist nasal spray flu vaccine. Yet the company's latest report showed just $3 million in FluMist revenue during the first half of the year, and sales of Synagis dropped 20% in the second quarter.

Still sick
AstraZeneca literally can't buy a winner right now. Residually, its dividend is enticing, but too many red flags exist to entice me to stick around. Until or unless the company can lock in another proven winner, be careful before you buy into AstraZeneca shares.

True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community.

Fool contributor Sean Williams does not own shares in any companies mentioned in this article. You can follow him on Motley Fool CAPS under the screen name UltraLong. The Fool owns shares of Teva Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. The Fool has a disclosure policy.

Read/Post Comments (1) | Recommend This Article (10)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 17, 2010, at 8:34 AM, DannyHaszard wrote:

    Eli Lilly Zyprexa suits

    They called it the *Five at Five* (5 mg at 5 pm to keep nursing home patients subdued and sleepy) and *VIVA ZYPREXA* (Zyprexa for everybody) campaigns to off label market Eli Lilly Zyprexa as a fix for unapproved usage.

    A New York Times report reviews what has been accomplished by multiple civil

    and criminal lawsuits against Big Pharma companies that have relied on fraud

    to market industry's worst pharmaceuticals--antipsychotic drugs--which have

    become industry's most profitable cash cow.

    "The new generation of antipsychotics has also become the single biggest

    target of the False Claims Act, a federal law once largely aimed at fraud

    among military contractors. Hundreds of millions of

    dollars or is currently under investigation for possible health care fraud."


    Daniel Haszard Zyprexa victim activist

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1332643, ~/Articles/ArticleHandler.aspx, 10/23/2016 2:48:05 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:03 PM
AZN $30.72 Down -0.28 -0.90%
AstraZeneca CAPS Rating: ****
TEVA $44.00 Down -0.21 -0.48%
Teva Pharmaceutica… CAPS Rating: ****